Affymetrix Announces Preliminary Revenue for First Quarter 2013

  Affymetrix Announces Preliminary Revenue for First Quarter 2013

Business Wire

SANTA CLARA, Calif. -- April 09, 2013

Affymetrix, Inc. (Nasdaq: AFFX) today reported that based on preliminary
financial data, the Company expects total revenue of approximately $78 million
for the first quarter of 2013, including revenue of approximately $19 million
from eBioscience. The Company expects to report cash-on-hand of at least $38
million as of March 31, 2013.

“Our revenues for the first quarter were below expectations, primarily due to
continued headwinds in our gene expression business across all regions, in
particular Japan, where we came in significantly short of plan,” said Frank
Witney, president and CEO. “Our genotyping and cytogenetics product lines
generated solid growth for the quarter as compared to 2012 and eBioscience
also had modest growth from the first quarter of last year. As reported
earlier, we ended the quarter with a major win, securing the largest biobank
genotyping study to date.”

“Cash-on-hand at the end of March was approximately $38 million, after
redeeming the remaining $3.9 million of our 3.5% convertible notes and
prepaying $3.2 million of our senior-secured debt,” said Tim Barabe, EVP and
chief financial officer. “Our senior secured debt is now at $70 million and
debt repayment continues to be one of our priorities in 2013.”

The Company will provide a more detailed business update and complete
financial information when it reports its first quarter results after the
close of the market on Tuesday, April 30, 2013. The Company is currently
observing a pre-earnings quiet period and will not make further comments about
its first quarter results in the interim.

Affymetrix’s management team will host a conference call on April 30, 2013 at
2:00 p.m. PT. A live webcast can be accessed by visiting the Investor
Relations section of the Company's website at In
addition, investors and other interested parties can listen by dialing
domestic: (877) 407-8291, international: (201) 689-8345.

A replay of this call will be available from 5:00 p.m. PT on April 30, 2013
until 8:00 p.m. PT on May 7, 2013 at the following numbers: domestic: (877)
660-6853, international: (201) 612-7415. The conference call passcode to
access the replay is 411930. An archived webcast of the conference call will
be available under the Investor Relations section of the Company's website.

About Affymetrix

Affymetrix's technologies are used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading academic,
government, and non-profit research institutes. More than 2,300 microarray
systems have been shipped around the world and more than 48,000 peer-reviewed
papers have been published citing our technologies. Affymetrix is
headquartered in Santa Clara, California, and has manufacturing facilities in
Cleveland, Ohio, San Diego, Vienna and Singapore. The Company has about 1,100
employees worldwide and maintains sales and distribution operations across
Europe, Asia, and Latin America. For more information about Affymetrix, please

Affymetrix has not filed the Form 10-Q for the first quarter of fiscal 2013.
As a result, all financial results described in this press release should be
considered preliminary, and are subject to change to reflect any necessary
corrections or adjustments, or changes in accounting estimates, that are
identified prior to the time the company is in a position to complete these

All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies" or the like.
Such statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected, including,
but not limited to: Affymetrix’s ability to stabilize its business and grow
revenue, Affymetrix's ability to timely and successfully integrate and realize
the anticipated strategic benefits and costs savings or other synergies of the
acquisition of eBioscience in a cost-effective manner while minimizing the
disruption to its business; risks that eBioscience's future performance may
not be consistent with its historical performance; risks relating to
Affymetrix's ability to make scheduled payments of the principal of, to pay
interest on or to refinance its indebtedness; risks relating to Affymetrix's
ability to successfully develop and commercialize new products, including its
ability to successfully develop and commercialize novel molecular solutions
based on eBioscience's portfolio of reagents; risks relating to past and
future acquisitions, including the ability of Affymetrix to successfully
integrate such acquisitions into its existing business; risks of Affymetrix's
ability to achieve and sustain higher levels of revenue, higher gross margins
and reduced operating expenses; risks relating to Affymetrix's ability to
generate cash after interest and principal payments; uncertainties relating to
technological approaches; risks associated with manufacturing and product
development; personnel retention; uncertainties relating to cost and pricing
of Affymetrix products; dependence on collaborative partners; uncertainties
relating to sole-source suppliers; uncertainties relating to FDA and other
regulatory approvals; competition; risks relating to intellectual property of
others and the uncertainties of patent protection and litigation. These and
other risk factors are discussed in Affymetrix's Annual Report on Form 10-K
for the year ended December 31, 2012, and other SEC reports, including its
Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in Affymetrix's expectations with regard thereto or any
change in events, conditions or circumstances on which any such statements are


Affymetrix, Inc.
Doug Farrell, 408-731-5285
Vice President of Investor Relations
Press spacebar to pause and continue. Press esc to stop.